Learn more about our Advocacy work.
WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for…
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
Learn how the Nairobi Protocol may support duty-free access for medical devices under new tariffs. Join us April 30, 2–3:30pm ET.
Washington, D.C.—AdvaMed, the Medtech Association, today released its “AI Policy Roadmap,” a detailed policy outline for Congress and the federal agencies with jurisdiction over medtech to consider in promoting the…
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.
WASHINGTON – AdvaMed, the Medtech Association, today commended Senators Mike Rounds (R-SD) and Martin Heinrich (D-NM) for introducing the Health Tech Investment Act (S. 1399). This landmark bipartisan legislation will…
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
Washington, D.C.– AdvaMed®, the Medtech Association, and nine additional organizations urged an exemption from tariffs for medical and dental supplies, equipment, and devices, citing concerns about increased costs resulting in supply…
Washington, D.C.– AdvaMed®, the Medtech Association, today released the following statement from President and CEO Scott Whitaker on the U.S. Senate’s confirmation of Dr. Mehmet Oz to serve as Administrator of…